Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Target Price at $85.33

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $85.3333.

Several research analysts have weighed in on PBH shares. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Jefferies Financial Group decreased their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research note on Monday, October 27th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Oppenheimer dropped their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st.

Prestige Consumer Healthcare Stock Up 1.1%

Prestige Consumer Healthcare stock opened at $59.67 on Monday. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare has a 1-year low of $57.25 and a 1-year high of $90.04. The company has a fifty day simple moving average of $61.46 and a 200 day simple moving average of $71.10. The company has a market cap of $2.87 billion, a P/E ratio of 14.01, a price-to-earnings-growth ratio of 1.93 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The company had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company’s quarterly revenue was down 3.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Research analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Norges Bank acquired a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at $41,848,000. Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 45.3% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after buying an additional 493,199 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Prestige Consumer Healthcare by 24.7% during the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after buying an additional 261,537 shares during the period. Tributary Capital Management LLC grew its stake in Prestige Consumer Healthcare by 157.3% in the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after buying an additional 231,969 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in Prestige Consumer Healthcare by 316.1% in the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after acquiring an additional 229,311 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.